ISN TrialWatch: A global library of kidney-related clinical trials

The ISN TrialWatch (formerly GTF – Global Trials Focus) is a bimonthly list identifying and summarizing recent interesting trials relevant to kidney disease.


ISN TrialWatch | Dec – Jan 2025

Enhancing quality of life: role of targeted exercises for children on hemodialysis
In this single-center study, 68 children on maintenance hemodialysis were randomized to receive either a 40-minute thrice weekly exercise program during hemodialysis for 2 months or routine care. A trained physical therapy researcher taught the exercises, including lower limb stretches (10 repetitions per muscle) during the first 20 minutes of the second hour of dialysis,

Trial of the month:

Global Kidney Trials Insights: A Guide for Everyone

To bring research closer to people living with kidney disease, ISN TrialWatch reviewers prepare special editions written in accessible language. These summaries help all readers, no matter their degree of scientific knowledge, understand key findings from impactful kidney trials.

Available summaries

ISN Global Kidney Care podcast: Spotlight on ISN-ACT

Hear insights into advancing global clinical trials from Michele Provenzano and Daniel O’Hara. The coordinators of the ISN-ACT Global Trials Focus shared their thoughts with ISN-ACT chair Meg Jardine and deputy chair Adeera Levin.

Listen to the episode

ISN Academy resources

Access a wide range of educational materials on clinical trials — including expert-led curriculum, webinar recordings, and WCN course sessions — all designed to support your learning and practice.

Explore the ISN Academy

#NephTrials (X Space discussions)

Join animated one-hour discussions on X, where ISN and #NephJC invite trial experts to share insights from their latest work. Engage directly, ask questions, and even request the mic to interact with principal investigators.

Discover #NephTrials

Contact the ISN Research team

Get in touch with us for inquiries, collaborations, or support at research@theisn.org.